Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
Ferring Pharmaceuticals is setting the record straight on fertility issues. nnBecause infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility. The issue is further compounded by stigma that may make men feel emasculated or embarrassed to be struggling with their fertility.
First Real-World Outcomes Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at DDW 2024
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
After Adstiladrin's FDA approval in late 2022, Ferring Pharmaceuticals finally established unfettered supply of the bladder cancer gene therapy earlier this year. Now, the company has locked down a long-term supplier in SK pharmteco.
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
Ferring`s Zomacton (Somatropin) Receives Suppl Approvals in the U.S